These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19289119)

  • 1. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
    Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
    Exp Neurol; 2009 Jun; 217(2):434-9. PubMed ID: 19289119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases.
    Ono K; Yamada M
    Neurobiol Dis; 2007 Feb; 25(2):446-54. PubMed ID: 17169566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal anti-inflammatory drugs have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.
    Hirohata M; Ono K; Morinaga A; Yamada M
    Neuropharmacology; 2008 Mar; 54(3):620-7. PubMed ID: 18164319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
    Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases.
    Ono K; Hirohata M; Yamada M
    Exp Neurol; 2007 Jun; 205(2):414-24. PubMed ID: 17425956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro.
    Ono K; Yamada M
    J Neurochem; 2006 Apr; 97(1):105-15. PubMed ID: 16524383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
    Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
    Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid from patients with multiple system atrophy promotes in vitro α-synuclein fibril formation.
    Hirohata M; Ono K; Morinaga A; Ikeda T; Yamada M
    Neurosci Lett; 2011 Mar; 491(1):48-52. PubMed ID: 21215793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization.
    Bosco DA; Fowler DM; Zhang Q; Nieva J; Powers ET; Wentworth P; Lerner RA; Kelly JW
    Nat Chem Biol; 2006 May; 2(5):249-53. PubMed ID: 16565714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-apoptotic protein glyceraldehyde-3-phosphate dehydrogenase promotes the formation of Lewy body-like inclusions.
    Tsuchiya K; Tajima H; Kuwae T; Takeshima T; Nakano T; Tanaka M; Sunaga K; Fukuhara Y; Nakashima K; Ohama E; Mochizuki H; Mizuno Y; Katsube N; Ishitani R
    Eur J Neurosci; 2005 Jan; 21(2):317-26. PubMed ID: 15673432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN
    J Neurochem; 2007 Oct; 103(1):17-37. PubMed ID: 17623039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis.
    Kamiyoshihara T; Kojima M; Uéda K; Tashiro M; Shimotakahara S
    Biochem Biophys Res Commun; 2007 Apr; 355(2):398-403. PubMed ID: 17300751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report.
    Wu CK
    Acta Neurol Taiwan; 2011 Mar; 20(1):4-14. PubMed ID: 21560084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro.
    Ono K; Hirohata M; Yamada M
    J Neurosci Res; 2007 May; 85(7):1547-57. PubMed ID: 17387689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of fibrillation process of alpha-synuclein at the initial stage.
    Tashiro M; Kojima M; Kihara H; Kasai K; Kamiyoshihara T; Uéda K; Shimotakahara S
    Biochem Biophys Res Commun; 2008 May; 369(3):910-4. PubMed ID: 18329380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
    Tavassoly O; Lee JS
    FEBS Lett; 2012 Sep; 586(19):3222-8. PubMed ID: 22771474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study.
    Minguez-Castellanos A; Chamorro CE; Escamilla-Sevilla F; Ortega-Moreno A; Rebollo AC; Gomez-Rio M; Concha A; Munoz DG
    Neurology; 2007 Jun; 68(23):2012-8. PubMed ID: 17548551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intralaminar nuclei of the thalamus in Lewy body diseases.
    Brooks D; Halliday GM
    Brain Res Bull; 2009 Feb; 78(2-3):97-104. PubMed ID: 18804518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.